Bentley Pharmaceuticals (BNT) Receives Spanish Approval for Generic Casodex
More News related to AZN
- Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community
- New Expanded Atlantis(TM) Patient-Specific Abutment Compatibility and Material Option for Straumann Implants
- MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
- MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
- Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018
More News related to BNT
- Notable Mergers and Acquisitions of the Day 7/23 (CSCO, BNT/TEVA, PHLY)
- Bentley (BNT) Shareholders Approve Merger with TEVA Pharma (TEVA)
- Bentley Pharma (BNT) Announces Adjustment To Teva (TEVA) Merger Price
- Bentley Pharmaceuticals (BNT) Misses Q1 EPS Views
- Unusual 11 Mid-Day Movers 3/31: ANST, VRTX, BNT, XJT Higher; SGP, FRP, TMA, MRK Lower
Bentley Pharmaceuticals, Inc. (NYSE: BNT) announced that its subsidiaries, Laboratorios Belmac and Laboratorios Davur, have received product approvals of bicalutamide from the Spanish Ministry of Health.
Bicalutamide is the generic equivalent to AstraZeneca Pharmaceuticals' (NYSE: AZN) Casodex. Bicalutamide is prescribed as a treatment to prevent the growth of prostate cancer by blocking the effects of androgens on the cancer cells. The treatment is a non-steroidal, anti-androgenic product orally administered as a 50 mg. tablet.
Related Categories
FDAStocks Mentioned
-17.22
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
